CTRI/2019/10/021507尚未招募2 期
A double-blind, placebo controlled, randomised trial using individualised homoeopathic treatment for modifying anger and thereby reducing blood pressure in patients of essential hypertension against standard care treatment - MAEHT
DrLeena Bagadia0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients of essential hypertension
排除标准
- •Patients having secondary hypertension
- •Pregnant and lactating women
- •Uncontrolled endocrine disorders
- •Severe psychiatric disorder
研究者
相似试验
已完成
2 期
A double-blind, placebo controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL1102 (VLA-4 antisense oligonucleotide) by subcutaneous injections in patients with relapsing remitting multiple sclerosis.Neurological - Multiple sclerosisMultiple SclerosisACTRN12608000226303Antisense Therapeutics Limited77
进行中（未招募）
1 期
A study of oral EMA401 in the treatment of pain following shingles to see if EMA401 can reduce the level of pain.EUCTR2011-000977-29-BGSpinifex Pharmaceuticals Pty Ltd172
已完成
1 期
A double-blind, placebo-controlled, randomised trial to determine the ocular pharmacokinetics and safety of oral FT011 in patients with glaucoma.ACTRN12618000033246Occurx Pty Ltd8
进行中（未招募）
不适用
A study of oral EMA401 in the treatment of pain following shingles to see if EMA401 can reduce the level of pain.postherpetic neuralgiaMedDRA version: 14.0Level: PTClassification code 10036376Term: Post herpetic neuralgiaSystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-000977-29-CZSpinifex Pharmaceuticals Pty Ltd172
进行中（未招募）
不适用
A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL 1102 (VLA-4 antisense oligonucleotide) by subcutaneous injections in patients with multiple sclerosis.To evaluate the efficacy of a selected treatment regimen of ATL 1102 in patients with Relapsing Remitting MS (RRMS) inflammatory lesions using MRI with gadolinium administration compared to placebo.EUCTR2006-004736-79-CZAntisense Therapeutics Ltd.80